Abstract
The clinical results obtained with a colchicine derivative, the trimethylcolchicinic acid methyl ether, are refrerred. 20 cases were treated, and respectively 14 Hodgkin's diseases, 3 reticulosarcomas, 3 carcinomas. The compound showed a considerable antitumoral activity and a scarce toxicity in general and on the hemopoietic function in particular. It may be considered as possessing the most important requisite for a cytostatic drug actually, that is the possibility of a prolonged and efficient administration without secondary toxical phaenomena. The association of trimethylcolchicinic acid methyl ether with other chemotherapeutical and radiotherapeutical means seem to be of interest and worth of further development.
Get full access to this article
View all access options for this article.